We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On today’s episode of Full Court Finance at Zacks we explore the market’s bullish outlook for 2021. The episode then dives into Apple (AAPL - Free Report) and Microsoft (MSFT - Free Report) to see if investors should consider buying either of the tech titans as we get closer to 2021.
Stocks fell early on Monday morning amid news that countries were racing to ban travel from the U.K. The moves are being made in an effort to prevent a highly infectious new strain of the coronavirus from spreading across more of Europe. But the downturn improved by mid-day.
The reason for the comeback likely stems from broader positivity as we head into 2021. Last week, healthcare workers in the U.S. began to receive Pfizer’s Covid-19 vaccine, and the FDA advisory panel recommended that Moderna’s vaccine be cleared for broad use. And federal officials expect that around 100 million Americans will get vaccinated by February or March.
Meanwhile, the second stimulus bill is ready for a final vote in Congress. This could prove key as many of the hardest-hit areas of the economy face a harsh winter, with another round of restrictions. Alongside the vaccine progress and another likely round of coronavirus aid, the earnings picture and interest rate environment both help further set up a bullish picture for 2021.
Despite the positivity, it might not be the best idea to dive into stocks that require tons of person-to-person contact just yet. And even though beaten-down spaces and cyclicals have made a comeback recently, technology is set to dominate the market and our lives.
With this in mind, we explore why investors might want to consider Apple and Microsoft stock as they rest below their highs.
The iPhone giant is poised to continue to grow its high-end consumer tech segment. Plus, its services unit that helps it compete against Netflix (NFLX - Free Report) , Spotify (SPOT - Free Report) , and others has amassed hundreds of millions of paid subscribers. And that’s just the start.
Microsoft stock jumped roughly 2% on Monday amid the broader downturn. The climb came after Citigroup analysts provided one of the most bullish MSFT targets on Wall Street. The call focused on the company’s growing cloud business that’s ready to help it expand for years alongside Amazon (AMZN - Free Report) and others.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Buy Apple and Microsoft Stock Heading Into 2021?
On today’s episode of Full Court Finance at Zacks we explore the market’s bullish outlook for 2021. The episode then dives into Apple (AAPL - Free Report) and Microsoft (MSFT - Free Report) to see if investors should consider buying either of the tech titans as we get closer to 2021.
Stocks fell early on Monday morning amid news that countries were racing to ban travel from the U.K. The moves are being made in an effort to prevent a highly infectious new strain of the coronavirus from spreading across more of Europe. But the downturn improved by mid-day.
The reason for the comeback likely stems from broader positivity as we head into 2021. Last week, healthcare workers in the U.S. began to receive Pfizer’s Covid-19 vaccine, and the FDA advisory panel recommended that Moderna’s vaccine be cleared for broad use. And federal officials expect that around 100 million Americans will get vaccinated by February or March.
Meanwhile, the second stimulus bill is ready for a final vote in Congress. This could prove key as many of the hardest-hit areas of the economy face a harsh winter, with another round of restrictions. Alongside the vaccine progress and another likely round of coronavirus aid, the earnings picture and interest rate environment both help further set up a bullish picture for 2021.
Despite the positivity, it might not be the best idea to dive into stocks that require tons of person-to-person contact just yet. And even though beaten-down spaces and cyclicals have made a comeback recently, technology is set to dominate the market and our lives.
With this in mind, we explore why investors might want to consider Apple and Microsoft stock as they rest below their highs.
The iPhone giant is poised to continue to grow its high-end consumer tech segment. Plus, its services unit that helps it compete against Netflix (NFLX - Free Report) , Spotify (SPOT - Free Report) , and others has amassed hundreds of millions of paid subscribers. And that’s just the start.
Microsoft stock jumped roughly 2% on Monday amid the broader downturn. The climb came after Citigroup analysts provided one of the most bullish MSFT targets on Wall Street. The call focused on the company’s growing cloud business that’s ready to help it expand for years alongside Amazon (AMZN - Free Report) and others.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>